News
Backed by $2 Million,
Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026
Copenhagen, Denmark - June 17, 2025
Copenhagen, Denmark - June 17, 2025 - Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend significant time manually flushing IV-lines to clear residual medication from IV lines.
Droplet IV achieves ISO 13485 Certification, marking major milestone toward market entry of automated IV line flushing device
Copenhagen, Denmark - April 23, 2025
Droplet IV, a Danish medical device company developing a unique and proprietary automatic IV line flushing device, has officially received its ISO 13485 certification. This internationally recognized quality standard is a critical milestone on the company’s fast-moving path to market - and comes at a pivotal moment as Droplet IV nears completion of its first investment round.
Droplet IV strengthens leadership and accelerates go-to-market strategy
Copenhagen Denmark - January 9, 2025
Droplet IV Aps (“Droplet IV”), a Danish medical device company developing a unique and proprietary automatic IV line flushing device, today announced a strengthening of its leadership team to accelerate its go-to-market efforts ahead of its first product launch in 2026. Henriette Kirkegaard has been appointed Chairperson of the Board, and Marcus Bech has been promoted to Chief Executive Officer (CEO). This leadership transition is part of Droplet IV’s ongoing efforts to prepare for the introduction of its first product and drive the company's growth in the coming years.
Leadership change to support market acceleration
As Droplet IV moves into 2025, co-founders and majority shareholders Tore Allerup and Marcus Bech have taken the decision to strengthen the company’s leadership structure. In addition to appointing Henriette Kirkegaard as Chairperson of the Board, Marcus Bech assumes the role of CEO, focusing on overseeing the company’s day-to-day operations.
Droplet IV strengthens leadership and accelerates go-to-market strategy
Copenhagen, Denmark - January 9, 2025
Droplet IV Aps (“Droplet IV”), a Danish medical device company developing a unique and proprietary automatic IV line flushing device, today announced a strengthening of its leadership team to accelerate its go-to-market efforts ahead of its first product launch in 2026. Henriette Kirkegaard has been appointed Chairperson of the Board, and Marcus Bech has been promoted to Chief Executive Officer (CEO). This leadership transition is part of Droplet IV’s ongoing efforts to prepare for the introduction of its first product and drive the company's growth in the coming years.
Leadership change to support market acceleration
As Droplet IV moves into 2025, co-founders and majority shareholders Tore Allerup and Marcus Bech have taken the decision to strengthen the company’s leadership structure. In addition to appointing Henriette Kirkegaard as Chairperson of the Board, Marcus Bech assumes the role of CEO, focusing on overseeing the company’s day-to-day operations.
TMCi Accelerator for US Market Expansion
1 May 2024
https://www.tmc.edu/
Droplet IV joins Texas Medical Center innovation (TMCi) accelerator for 6 months to facilitate market expansion into the US healthcare.
MedWatch Article
16 Jan 2024
Droplet IV has been granted the special Safer Technologies Program (STeP) designation by the FDA, which will significantly reduce the time it takes to obtain regulatory approval.
This allows Droplet IV to adhere their project timeline and eventually enter the US market in 2025.
TV2 Bornholm News
3 November 2023
Tore was interviewed at Bornholm’s Hospital, where the discovery took place. Droplet IV was developed as part of the BioMedical Design Novo Nordisk Foundation Fellowship Programme during a four-month stay at the hospital in 2021.
Entering BioInnovation Institute
23 April 2023
Only a few months after receiving the honorable award from Danish Tech Challenge, Droplet IV entered the BioInnovation Institute’s Venture Lab program. It offers help to early-stage start-ups within human health and planetary health.
Winning Danish Tech Challenge
20 January 2023
Droplet IV won the Danish Tech Challenge. Seen here awarded the winning prize by His Royal Highness the Crown Prince.
Life Science Award
Marts 2023
Droplet IV received in 2022 a Life Science Micro grant from Bristol Myers Squibb and the Foundation for Entrepreneurship.